Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Silibinin is the primary active flavonolignan compound found in milk thistle, representing 50-70% of the silymarin complex. It functions primarily as a hepatoprotective agent by stabilizing hepatocyte membranes and inhibiting lipid peroxidation in liver tissue.
Origin & History
Silibinin is a flavonolignan primarily derived from the seeds of the milk thistle plant (Silybum marianum), comprising the major active component of silymarin extract. It is isolated and purified through solvent extraction (typically ethanol or methanol) from the plant's fruits and seeds for pharmaceutical use in capsules or extracts.
Research Narrative (Provisional)
Clinical evidence includes a 568-patient randomized controlled trial testing 210mg daily silibinin alongside TB drugs (PMC4443182), and a 30-patient double-blind RCT in rheumatoid arthritis (PMC4927723). Two meta-analyses evaluated silibinin for liver conditions: one analyzing 16 RCTs in traditional Chinese medicine combinations (PMID: 38306552) and another for alcoholic liver disease (PMC11832396).
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Silibinin (Flavonolignan) is a bioactive compound rather than a traditional nutrient, so it lacks conventional macronutrient/micronutrient profiles. It is the primary active constituent of silymarin, extracted from milk thistle (Silybum marianum) seeds, comprising approximately 50-70% of silymarin extract by weight. As a pure compound, it is typically standardized to >95% purity in pharmaceutical/research preparations. Silibinin exists as a diastereomeric mixture of silybin A and silybin B in approximately equal proportions. Molecular weight: 482.44 g/mol. It contains a flavonoid (taxifolin) linked to a phenylpropanoid (coniferyl alcohol) via an ether bond. Bioavailability is notably poor when administered orally in free form, with absolute bioavailability estimated at <1% due to low aqueous solubility and extensive first-pass metabolism; plasma half-life is approximately 6 hours. Bioavailability is significantly enhanced via phospholipid complexes (Siliphos/Silymarin-phosphatidylcholine complex), which improve absorption 4-10 fold. IV formulations (e.g., Legalon SIL) bypass bioavailability limitations entirely. It undergoes hepatic glucuronidation and sulfation, with biliary excretion being the primary elimination route (~80%). Typical therapeutic doses range from 140-800 mg/day orally; clinical trials for liver protection in TB used doses around 140-420 mg/day. No caloric or macronutrient contribution is clinically relevant at therapeutic doses.
Reported Mechanism (Provisional)
Silibinin stabilizes hepatocyte cell membranes by binding to phosphatidylcholine and preventing membrane damage from free radicals. The compound inhibits 5-lipoxygenase and cyclooxygenase enzymes, reducing inflammatory prostaglandin and leukotriene production. It also modulates nuclear factor-kappa B (NF-κB) signaling pathways to decrease hepatic inflammation.
Clinical Narrative (Provisional)
A randomized controlled trial of 568 tuberculosis patients showed silibinin reduced AST levels at 2-4 weeks and alkaline phosphatase at 8 weeks during anti-TB treatment. The same study demonstrated improved sputum clearance with 98.30% negativity rates versus 92.98% in controls (P<0.05). However, overall hepatotoxicity rates remained similar between treatment and control groups. Current clinical evidence is limited primarily to tuberculosis-related liver protection studies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.